New Ebola Variant Identified in DRC–Uganda Outbreak as Repurposed Drug Shows Promise

Scientists Identify a New Ebola Variant in the 2026 DRC–Uganda Outbreak

Researchers have identified a genetically distinct new Ebola variant behind the 2026 Democratic Republic of the Congo (DRC) and Uganda outbreak, publishing their findings in The Lancet and Nature Medicine while the response is still underway. The variant belongs to the Bundibugyo ebolavirus (BDBV) species — a rare and highly contagious form of Ebola for which there are currently no approved vaccines or treatments specifically designed for the disease. In a parallel development, computer modelling suggests a repurposed antiviral drug, remdesivir, may be effective against the new variant, and the drug is now being evaluated in a clinical trial in Africa.

The work is the result of an international collaboration involving scientists, clinicians, and public health teams in Uganda, the DRC, and Canada, and it marks an important step toward understanding — and potentially treating — one of the most challenging Ebola outbreaks in recent history.

What Is the 2026 Ebola Outbreak?

The outbreak was officially declared on 15 May 2026 in northeastern DRC, after laboratory analysis confirmed Bundibugyo virus disease (BVD) in eight patient samples. On 16 May, the World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern (PHEIC), its highest alert level.

Key numbers from the response so far:

• DRC: More than 3,200 confirmed cases and over 1,400 reported deaths as of late July 2026, with case numbers continuing to rise in some areas.
• Uganda: 20 confirmed cases and two deaths; the last confirmed case was reported on 21 June, and the final patient was discharged from the Mulago National Referral Isolation Centre on 16 July.
• Affected areas: In DRC, the outbreak has spread across Haut-Uélé, Ituri, North Kivu, South Kivu, and Tshopo provinces. Related cases were also reported in Uganda’s capital, Kampala.
• Scale: This is the 17th Ebola disease outbreak the DRC has experienced since 1976, and only the third to involve Bundibugyo virus — following outbreaks in Uganda in 2007–2008 and in DRC in 2012.

Past Bundibugyo outbreaks have carried case fatality rates of roughly 30–50%, underscoring the seriousness of the current situation. Unlike Ebola virus disease caused by the Zaire species — which has licensed vaccines and treatments — there is no approved vaccine or specific therapeutic for BDBV.

A New Variant: What the Research Found

Within weeks of the PHEIC declaration, an international team — including Dr. Anuj Kumar and Dr. David Kelvin of Dalhousie University’s Laboratory of Emerging Infectious Diseases — published two major studies. The first, in The Lancet, identified the virus driving the outbreak as a genetically distinct variant of Bundibugyo ebolavirus. A second paper in Nature Medicine confirmed the emergence of the variant, and a further study in the Journal of Infection examined potential treatment options.

Researchers in Uganda and the DRC performed the virus sequencing, while the Dalhousie team analyzed the genetic data and built a mutation map showing how the virus has changed over time.

“This is a novel variant of the virus circulating in the DRC,” says Dr. Kumar. “From the genomic side, we can build a mutation map, see what changes have occurred, and better understand what those changes in the virus might mean.”

The rapid publication of both studies gave researchers and public health officials access to critical information while the outbreak response was still unfolding — a shift from the months-long timelines that often delay scientific publication.

Why a Repurposed Drug Could Matter

Because no therapies are approved specifically for BDBV, the team investigated whether an existing drug could be repurposed. Using advanced computer modelling, they tested remdesivir triphosphate — the active form of remdesivir, an antiviral widely used during the COVID-19 pandemic — against the new variant.

Their analysis suggested the drug targets a critical part of the virus responsible for replication, a region that has remained unchanged despite the emergence of the new variant. The finding generated enough interest that the drug is now being evaluated through an ongoing clinical trial in Africa.

Dr. Kelvin notes the approach shows how computational tools can accelerate outbreak responses: rather than developing a brand-new drug from scratch, researchers can quickly evaluate whether existing treatments might work against emerging diseases.

The Challenge of Early Diagnosis

One of the biggest hurdles in this outbreak is diagnosis. In its early stages, Ebola infection mimics the flu or general malaise.

“When somebody is infected with Ebola, the initial symptoms mimic the flu or simply feeling unwell,” says Dr. Kelvin. “There are currently no good diagnostic tools available to catch cases in the early stages.”

Early diagnosis matters because early supportive care is lifesaving — and because delays allow the virus to spread silently within communities.

Global Response Underway

International agencies are mobilizing at scale:

• WHO is coordinating the PHEIC response alongside ministries of health in the DRC and Uganda.
• CDC reports that roughly 400 staff are involved in the response, including more than 120 people deployed to affected countries, with guidance issued for travelers returning from affected areas.
• Doctors Without Borders (MSF) teams are providing care in communities affected by conflict and limited access to health services.

What Happens Next

The discovery of the new variant and the promise of a repurposed treatment are significant, but major gaps remain: there is still no licensed BDBV vaccine, no specific antiviral approved for this species, and diagnostic tools need improvement. The ongoing clinical trial of remdesivir will provide the first real-world data on whether the repurposed drug can improve survival.

As Dr. Kumar puts it: “We’re optimistic that the information we’re generating will be useful for researchers and public health teams working to control this outbreak.”

For the public, the key message is straightforward: Ebola remains a serious but containable disease when caught early, and the international research community is applying lessons from COVID-19 to fight this outbreak faster than ever before.

Frequently Asked Questions

What is Bundibugyo ebolavirus?

Bundibugyo ebolavirus (BDBV) is one of several viruses that cause Ebola disease. It is rarer than the Zaire species but causes the same severe illness, with case fatality rates historically ranging from 30% to 50%.

Is there a vaccine for this Ebola variant?

No. There is currently no licensed vaccine or approved treatment specifically designed for Bundibugyo virus, which is why the outbreak has been so difficult to control.

Could remdesivir treat the new Ebola variant?

Computer modelling suggests remdesivir triphosphate targets a conserved region of the virus responsible for replication that has not changed in the new variant. The drug is now being tested in a clinical trial in Africa.

How is this outbreak different from previous Ebola outbreaks?

It is the first outbreak involving a genetically distinct variant of Bundibugyo virus, and it has been declared a Public Health Emergency of International Concern. It is also the DRC’s 17th Ebola outbreak since 1976.

What should travelers to affected areas do?

Health agencies advise travelers to DRC, Uganda, and neighboring regions to monitor for symptoms such as fever, fatigue, and muscle pain for 21 days after possible exposure, and to seek medical care immediately if symptoms develop.